Heidy King-Jones Sells 400 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock

Posted by Brian Himes on Sep 5th, 2026

Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) insider Heidy King-Jones sold 400 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $90.00, for a total transaction of $36,000.00. Following the completion of the transaction, the insider owned 2,845 shares in the company, valued at $256,050. The trade was a 12.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Heidy King-Jones also recently made the following trade(s):

On Tuesday, September 1st, Heidy King-Jones sold 27,999 shares of Spyre Therapeutics stock. The stock was sold at an average price of $87.31, for a total transaction of $2,444,592.69.

Spyre Therapeutics Price Performance

Shares of NASDAQ SYRE opened at $88.98 on Friday. The company has a market capitalization of $7.82 billion, a P/E ratio of -45.63 and a beta of 2.99. The company has a 50 day simple moving average of $98.05 and a 200-day simple moving average of $74.63. Spyre Therapeutics, Inc. has a 1 year low of $14.51 and a 1 year high of $110.18.

Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.40. As a group, research analysts expect that Spyre Therapeutics, Inc. will post -2.62 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in SYRE. California State Teachers Retirement System grew its stake in shares of Spyre Therapeutics by 9,594.0% in the second quarter. California State Teachers Retirement System now owns 5,742,912 shares of the company’s stock worth $509,856,000 after acquiring an additional 5,683,670 shares in the last quarter. Perceptive Advisors LLC raised its stake in shares of Spyre Therapeutics by 149.6% in the fourth quarter. Perceptive Advisors LLC now owns 3,069,225 shares of the company’s stock valued at $100,548,000 after acquiring an additional 1,839,780 shares in the last quarter. Janus Henderson Group PLC raised its stake in shares of Spyre Therapeutics by 13,969.3% in the fourth quarter. Janus Henderson Group PLC now owns 1,829,009 shares of the company’s stock valued at $59,918,000 after acquiring an additional 1,816,009 shares in the last quarter. RA Capital Management L.P. purchased a new position in Spyre Therapeutics in the fourth quarter valued at $53,124,000. Finally, Remedium Capital Partners LLC purchased a new position in Spyre Therapeutics in the fourth quarter valued at $47,706,000. Institutional investors and hedge funds own 80.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on SYRE shares. Guggenheim raised their price objective on Spyre Therapeutics from $115.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Spyre Therapeutics in a research note on Tuesday. BTIG Research dropped their price target on shares of Spyre Therapeutics from $132.00 to $121.00 and set a “buy” rating for the company in a research report on Wednesday, August 26th. Robert W. Baird set a $120.00 price target on shares of Spyre Therapeutics in a research note on Wednesday, August 5th. Finally, Mizuho upped their price objective on shares of Spyre Therapeutics from $84.00 to $120.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $109.69.

Get Our Latest Stock Report on SYRE

Key Headlines Impacting Spyre Therapeutics

Here are the key news stories impacting Spyre Therapeutics this week:

Positive Sentiment: Management will participate in the Citi BioPharma Back to School Conference on September 9, the Wells Fargo Healthcare Conference on September 10, and the Stifel Immunology and Inflammation Forum on September 23. These events could provide updates on Spyre’s clinical programs, development strategy, and potential catalysts. Spyre Therapeutics to Participate in Upcoming September Investor Conferences
Positive Sentiment: Spyre’s independent compensation committee approved stock options covering 2,106 shares and 745 restricted stock units for a new non-executive employee. The awards were intended to secure the employee’s acceptance and may support the company’s ability to recruit talent, although the equity issuance has a modest dilution effect. Spyre Therapeutics Announces Grants of Inducement Awards
Neutral Sentiment: Spyre’s latest quarterly loss of $0.36 per share was better than the expected $0.76 loss. However, the company remains unprofitable, with analysts forecasting a full-year loss of approximately $2.62 per share. The earnings beat alone has not provided a lasting catalyst.
Negative Sentiment: Several insiders reported sales totaling roughly 69,000 shares. CEO Cameron Turtle sold 15,000 shares, CFO Scott Burrows sold 25,732 shares, and Heidy King-Jones sold 28,399 shares. The transactions were made under pre-arranged Rule 10b5-1 plans; Burrows said his sales covered tax withholding obligations. Even so, the volume of selling—particularly King-Jones’s substantial reduction in ownership—could weigh on investor sentiment. Spyre Therapeutics Insider Trading
Negative Sentiment: A Zacks report noted that SYRE had declined 16.6% since its latest earnings release, suggesting investors remain focused on the need for clinical progress and additional company-specific catalysts. Spyre Therapeutics Down 16.6% Since Last Earnings Report

About Spyre Therapeutics

(Get Free Report)

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.